PTC Therapeutics, Inc. or Celldex Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Revenue Race: PTC vs. Celldex from 2014-2023

__timestampCelldex Therapeutics, Inc.PTC Therapeutics, Inc.
Wednesday, January 1, 2014358600022963000
Thursday, January 1, 2015548000036766000
Friday, January 1, 2016678600082705000
Sunday, January 1, 201712743000194392000
Monday, January 1, 20189538000264734000
Tuesday, January 1, 20193573000306980000
Wednesday, January 1, 20207418000380766000
Friday, January 1, 20214651000538593000
Saturday, January 1, 20222357000698801000
Sunday, January 1, 20236883000937822000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the competitive world of biotechnology, PTC Therapeutics, Inc. and Celldex Therapeutics, Inc. have been on a fascinating revenue journey over the past decade. From 2014 to 2023, PTC Therapeutics has consistently outpaced Celldex, showcasing a remarkable growth trajectory. Starting with a modest revenue in 2014, PTC Therapeutics saw an impressive increase of over 3,900% by 2023, reaching nearly $938 million. In contrast, Celldex Therapeutics experienced a more modest growth, with its revenue peaking in 2017 and then fluctuating, ending 2023 with a revenue of approximately $6.9 million.

This revenue disparity highlights PTC's strategic advancements and market positioning, making it a leader in the biotech sector. As the industry evolves, these companies' financial performances offer valuable insights into their operational strategies and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025